文献速递乳腺MR

7.0-T MRI组织钠浓度定量作为乳腺癌化疗反应早期标志物的可行性研究

Tissue Sodium Concentration Quantification at 7.0-T MRI as an Early Marker for Chemotherapy Response in Breast Cancer: A Feasibility Study.
PubMed 文献 · Radiology · 2021-02-16

这项前瞻性可行性研究纳入15例原发性乳腺癌女性和6例健康女性,在化疗前及第一、二周期后行7.0-T 23Na MRI定量组织钠浓度(TSC)与肿瘤大小。结果显示,第一周期后TSC预测病理完全缓解的AUC为0.96(95% CI: 0.86, 1.00; P < .001),第二周期后AUC为1.000(95% CI: 1.00; P < .001),提示TSC下降可能指示治疗反应。

要点

  • 第一周期化疗后TSC预测pCR的AUC为0.96(95% CI: 0.86, 1.00; P < .001)。
  • 第二周期化疗后TSC预测pCR的AUC为1.000(95% CI: 1.00; P < .001)。
  • pCR组第一周期后TSC降低12.0%(8.3 mmol/L),非pCR组降低4.7%(3.4 mmol/L)。

关键影像表现/征象

  • pCR组基线平均肿瘤大小为7.0 cm2 ± 5.0,非pCR组为19.0 cm2 ± 12.0。
  • 第一周期化疗后,pCR组肿瘤大小缩小32.9%(2.3 cm2/7.0 cm2),非pCR组缩小15.3%(2.9 cm2/19.0 cm2)。
  • pCR组基线平均TSC为69.4 mmol/L ± 6.1,第一周期后降低12.0%(8.3 mmol/L);非pCR组基线平均TSC为71.7 mmol/L ± 5.7,第一周期后降低4.7%(3.4 mmol/L)。

诊断标准与关键数值

  • 第一周期化疗后肿瘤大小缩小预测pCR的AUC为0.73(95% CI: 0.09, 0.50; P = .12)。
  • 第二周期化疗后肿瘤大小缩小预测pCR的AUC为0.93(95% CI: 0.04, 0.60; P < .001)。
  • 第一周期化疗后TSC预测pCR的AUC为0.96(95% CI: 0.86, 1.00; P < .001)。
  • 第二周期化疗后TSC预测pCR的AUC为1.000(95% CI: 1.00; P < .001)。

临床应用与阅片要点

  • 7.0-T 23Na MRI TSC定量可用于乳腺癌新辅助化疗早期治疗结局预测的可行性探索。
  • TSC降低可能指示癌症治疗反应,pCR组第一周期后降低12.0%(8.3 mmol/L),非pCR组降低4.7%(3.4 mmol/L)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Tissue sodium concentration (TSC) is elevated in breast cancer and can determine chemotherapy response. Purpose To test the feasibility of using a sodium 23 (23Na) MRI protocol at 7.0 T for TSC quantification to predict early treatment outcomes of neoadjuvant chemotherapy in breast cancer and to determine whether those quantitative values provide additional information about efficacy. Materials and Methods Women with primary breast cancer were included in this prospective study. From July 2017 to June 2018, participants underwent 7.0-T 23Na MRI. Multichannel data sets were acquired with a density-adapted, three-dimensional radial projection reconstruction pulse sequence. Two-dimensional tumor size and TSC were evaluated before and after the first and second chemotherapy cycle, and statistical tests were performed based on the presence or absence of a pathologic complete response (pCR). Results Fifteen women with breast cancer and six healthy women were enrolled. The mean baseline tumor size in women with a pCR was 7.0 cm2 ± 5.0 (standard deviation), and the mean baseline tumor size in women without a pCR was 19.0 cm2 ± 12.0. After the first chemotherapy cycle, women with a pCR showed a reduced tumor size of 32.9% (2.3 cm2/7.0 cm2), compared with 15.3% (2.9 cm2/19.0 cm2) in those without a pCR. The areas under the receiver operating characteristic curve for tumor size reduction after the first and second chemotherapy cycle were 0.73 (95% CI: 0.09, 0.50; P = .12) and 0.93 (95% CI: 0.04, 0.60; P < .001), respectively. Women with a pCR had a mean baseline TSC of 69.4 mmol/L ± 6.1, with a reduction of 12.0% (8.3 mmol/L), whereas those without a pCR had a mean baseline TSC of 71.7 mmol/L ± 5.7, with a reduction of 4.7% (3.4 mmol/L) after the first cycle. The areas under the receiver operating characteristic curve for TSC after the first and second cycles were 0.96 (95% CI: 0.86, 1.00; P < .001) and 1.000 (95% CI: 1.00, P < .001), respectively. Conclusion Using 7.0-T MRI for tissue sodium concentration quantification to predict early treatment outcomes of neoadjuvant chemotherapy in breast cancer is feasible, with reduced tissue sodium concentration indicative of cancer response. © RSNA, 2021 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Zaric O, Farr A, Minarikova L, et al. Tissue Sodium Concentration Quantification at 7.0-T MRI as an Early Marker for Chemotherapy Response in Breast Cancer: A Feasibility Study. Radiology. 2021. PMID: 33591888. doi:10.1148/radiol.2021201600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。